Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This Bitcoin-focused microcap is building a treasury strategy centered on accumulating BTC (click to learn more) Laser Photonics Reports Full Year Total Net Sales Increase of 144% in Q4 2025 Financial Results (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Defence Therapeutics Inc C.DTC

Alternate Symbol(s):  DTCFF

Healthcare Biotechnology
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting... see more

Recent & Breaking News (CSE:DTC)

Defence Therapeutics Announces Warrant Terms Amendment

Newsfile March 20, 2026

Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000

Newsfile March 9, 2026

Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March

Newsfile March 2, 2026

Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million

Newsfile February 27, 2026

Defence Therapeutics Aligns Accum ADC Strategy Through Multidisciplinary Scientific Advisory Board

Newsfile February 10, 2026

Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform

Newsfile February 4, 2026

Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline

Newsfile January 28, 2026

Defence Therapeutics Sharpens Strategic Focus on Precision Drug Delivery to Unlock the Full Potential of Cancer Biologics

Newsfile January 21, 2026

Defence Therapeutics Announces AGM Results and Provides Corporate Updates

Newsfile December 10, 2025

Defence Therapeutics Announces Formation of Scientific Advisory Board to Guide Advancement of Accum-Enhanced Antibody Drug Conjugate Programs

Newsfile December 4, 2025

Defence Therapeutics Announces Convertible Debenture Conversion

Newsfile November 21, 2025

Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using Its Proprietary Accum Technology

Newsfile November 19, 2025

Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs

Newsfile November 6, 2025

CSE Bulletin: MOC Eligibility Update

Newsfile November 4, 2025

Defence Therapeutics Demonstrates Strong Preclinical in Vivo Efficacy Results Evaluating Accum-Kadcyla in Breast Cancer Models

Newsfile November 4, 2025

Defence to Present New Scientific Data on Its ADC-Enhancing Accum Technology at the World ADC Conference in San Diego, USA, November 4-5, 2025

Newsfile October 23, 2025

Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025

Newsfile October 6, 2025

Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations

Newsfile October 2, 2025

Defence's Director, Strategy & Business Advisor Dr. Amie Phinney Discusses the Accum Platform on Money Talk Radio with Ellis Martin

Newsfile September 23, 2025

Defence Therapeutics Appoints Dr. Amie Phinney as Director

Newsfile September 16, 2025

Podcasts